Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):325–330. doi: 10.1128/aac.40.2.325

Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

J L Fournier 1, F Ramisse 1, A C Jacolot 1, M Szatanik 1, O J Petitjean 1, J M Alonso 1, M R Scavizzi 1
PMCID: PMC163110  PMID: 8834874

Abstract

The in vivo efficacies of piperacillin, piperacillin plus tazobactam, ticarcillin, ticarcillin plus clavulanic acid, piperacillin plus clavulanic acid, and cefotaxime were compared in a mouse model of pneumonia induced by the SHV-1 beta-lactamase-producer Klebsiella pneumoniae. Each antibiotic was injected either once intraperitoneally at 24 h postinfection or at repeated times during 24 h. The efficacies of the drugs and therapeutic protocols were assessed by counting viable bacteria recovered from the lungs of mice sacrificed at selected times. No emergence of beta-lactam-resistant organisms was detected. Ticarcillin at 300 mg/kg was ineffective. Repeated injections of piperacillin at 300 mg/kg, either alone or in combination with tazobactam (8:1), led to a significant decrease in bacterial counts, but this was followed by bacterial regrowth. The pharmacokinetic analysis demonstrated that this short-lasting antibacterial effect was not due to a failure of piperacillin and/or tazobactam to penetrate the lungs. The combinations of ticarcillin at 300 mg/kg plus clavulanic acid (15:1) and piperacillin at 300 mg/kg plus tazobactam (4:1) were proven to be effective in that they decreased the bacterial burden in the lungs from 10(5) to < 10(3) CFU. This dose effect of tazobactam can be explained by its dose-dependent penetration in the lungs. Cefotaxime at 100 mg/kg and the combination of piperacillin (slightly hydrolyzed by SHV-1) at 300 mg/kg plus clavulanic acid (15:1) led to the best efficacy. Both of these treatments induced a decrease in bacterial counts of nearly 4 log10 units. The survival rates correlated with the quantitative measurements of in vivo bacterial killing. These experimental results obtained from the restricted animal model used here may help in the design of further protocols for clinical trials.

Full Text

The Full Text of this article is available as a PDF (226.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beale A. S., Gisby J. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis. Infection. 1991 Mar-Apr;19(2):101–105. doi: 10.1007/BF01645577. [DOI] [PubMed] [Google Scholar]
  2. Bonacorsi S. P., Scavizzi M. R., Guiyoule A., Amouroux J. H., Carniel E. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother. 1994 Mar;38(3):481–486. doi: 10.1128/aac.38.3.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boon R. J., Beale A. S., Sutherland R. Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo. Antimicrob Agents Chemother. 1986 May;29(5):838–844. doi: 10.1128/aac.29.5.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bush K., Macalintal C., Rasmussen B. A., Lee V. J., Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993 Apr;37(4):851–858. doi: 10.1128/aac.37.4.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elwell A., Wise R. The beta-lactamase stability of acylureidopenicillins. J Antimicrob Chemother. 1982 Dec;10(6):560–561. doi: 10.1093/jac/10.6.560-a. [DOI] [PubMed] [Google Scholar]
  6. Frimodt-Møller N., Bentzon M. W., Thomsen V. F. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis. 1986 Sep;154(3):511–517. doi: 10.1093/infdis/154.3.511. [DOI] [PubMed] [Google Scholar]
  7. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  8. Jehl F., Gallion C., Monteil H. High-performance liquid chromatography of antibiotics. J Chromatogr. 1990 Oct 12;531:509–548. doi: 10.1016/s0378-4347(00)82293-8. [DOI] [PubMed] [Google Scholar]
  9. Kuck N. A., Jacobus N. V., Petersen P. J., Weiss W. J., Testa R. T. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969. doi: 10.1128/aac.33.11.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lemaitre B. C., Mazigh D. A., Scavizzi M. R. Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection. Antimicrob Agents Chemother. 1991 Sep;35(9):1785–1790. doi: 10.1128/aac.35.9.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mentec H., Vallois J. M., Bure A., Saleh-Mghir A., Jehl F., Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother. 1992 Sep;36(9):1883–1889. doi: 10.1128/aac.36.9.1883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mouton Y., Beuscart C., Soussy C. Efficacité et tolérance de la pipéracilline chez 333 malades. Presse Med. 1986 Dec 20;15(46):2347–2350. [PubMed] [Google Scholar]
  13. Nassif X., Sansonetti P. J. Correlation of the virulence of Klebsiella pneumoniae K1 and K2 with the presence of a plasmid encoding aerobactin. Infect Immun. 1986 Dec;54(3):603–608. doi: 10.1128/iai.54.3.603-608.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reeves D. S., Holt H. A., Bywater M. J., MacGowan A. P. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing. J Antimicrob Chemother. 1993 Jul;32(1):51–61. doi: 10.1093/jac/32.1.51. [DOI] [PubMed] [Google Scholar]
  15. Roncoroni A. J., Manuel C., Nedjar C., Bauchet J., Mariani D. Cefamandole bone diffusion in patients undergoing total hip replacement. Chemotherapy. 1981;27(3):166–172. doi: 10.1159/000237973. [DOI] [PubMed] [Google Scholar]
  16. SZYBALSKI W., BRYSON V. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol. 1952 Oct;64(4):489–499. doi: 10.1128/jb.64.4.489-499.1952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Scavizzi M. R., Alonso J. M., Philippon A. M., Jupeau-Vessieres A. M., Guiyoule A. Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection. Antimicrob Agents Chemother. 1987 Apr;31(4):523–526. doi: 10.1128/aac.31.4.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Scavizzi M. R., Elbhar A., Fénelon J. P., Bronner F. D. Multidimensional analysis for interpreting antibiotic susceptibility data. Antimicrob Agents Chemother. 1993 Apr;37(4):929–929. doi: 10.1128/aac.37.4.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sörgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):39–60. doi: 10.1093/jac/31.suppl_a.39. [DOI] [PubMed] [Google Scholar]
  20. Vernet V., Philippon A., Madoulet C., Vistelle R., Jaussaud R., Chippaux C. Virulence factors (aerobactin and mucoid phenotype) in Klebsiella pneumoniae and Escherichia coli blood culture isolates. FEMS Microbiol Lett. 1995 Jul 15;130(1):51–57. doi: 10.1016/0378-1097(95)00141-Q. [DOI] [PubMed] [Google Scholar]
  21. Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES